Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclic nucleotide-gated channel subunit beta 3 (CNGB3) is a regulatory subunit of cone CNG channels, which form heterotetramers composed typically of three CNGA3 subunits and one CNGB3 subunit in humans. These channels transduce chemical signals induced by light into electrical signals crucial for color vision. CNGB3 contributes to unique structural and functional properties of cone channels, influencing ion selectivity and channel gating. Mutations in CNGB3 are a major genetic cause of achromatopsia, a congenital inability to perceive color, and related degenerative retinal diseases. CNGB3 does not form functional channels on its own but modulates channel properties when assembled with CNGA3.
Drugs or molecules that modulate CNG channels typically alter channel gating by binding or interfering with the cyclic nucleotide-binding domain, affecting ion flow and photoreceptor response.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic nucleotide-gated channel subunit beta 3 (CNGB3).